OpenNashEarnings

Health Insurance · NYSE: ELV

Elevance Health earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 27 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Elevance is pushing Carelon's integrated, value-based care model across its health plans and to outside clients, citing a 15% cut in avoidable admissions in its cancer program.

Elevance leaned on Carelon this quarter, linking pharmacy, behavioral health and home-based care to its health plans. Management says its cancer program cut avoidable admissions and its Elevate cost-management platform has flagged savings. Individual ACA enrollment held up better than expected after enhanced subsidies expired, with members shifting to lower-premium bronze plans. Medicaid, Medicare Advantage and employer risk membership kept shrinking. In commercial, several large employers returned to Anthem, drawn by integrated medical and pharmacy offerings.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$51.4B+1.4% y/yQ3 2026
Q4 2024: $45.4B (worked out from the annual figure)Q4 ’24$45.4BQ1 2025: $48.9BQ1 ’25$48.9BQ2 2025: $49.8BQ2 ’25$49.8BQ3 2025: $50.7BQ3 ’25$50.7BQ4 2025: $49.7B (worked out from the annual figure)Q4 ’25$49.7BQ1 2026: $50.2BQ1 ’26$50.2BQ2 2026: $50.5BQ2 ’26$50.5BQ3 2026: $51.4BQ3 ’26$51.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$45.4B *
Q1 2025$48.9B
Q2 2025$49.8B
Q3 2025$50.7B
Q4 2025$49.7B *
Q1 2026$50.2B
Q2 2026$50.5B
Q3 2026$51.4B
Diluted EPS (GAAP)$6.27+17.9% y/yQ3 2026
Q1 2025: $9.61Q1 ’25$9.61Q2 2025: $7.72Q2 ’25$7.72Q3 2025: $5.32Q3 ’25$5.32Q1 2026: $8.00Q1 ’26$8.00Q2 2026: $6.71Q2 ’26$6.71Q3 2026: $6.27Q3 ’26$6.27
Data
Q1 2025$9.61
Q2 2025$7.72
Q3 2025$5.32
Q1 2026$8.00
Q2 2026$6.71
Q3 2026$6.27

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin2.5%−0.1 pts y/yQ3 2026
Q4 2024: 1.5%Q4 ’241.5%Q1 2025: 6.5%Q1 ’256.5%Q2 2025: 4.9%Q2 ’254.9%Q3 2025: 2.6%Q3 ’252.6%Q4 2025: 0.6%Q4 ’250.6%Q1 2026: 4.2%Q1 ’264.2%Q2 2026: 3.5%Q2 ’263.5%Q3 2026: 2.5%Q3 ’262.5%
Data
Q4 20241.5%
Q1 20256.5%
Q2 20254.9%
Q3 20252.6%
Q4 20250.6%
Q1 20264.2%
Q2 20263.5%
Q3 20262.5%
Free cash flow$1.0B+29.0% y/yQ3 2026
Q4 2024: $384.0MQ4 ’24$384.0MQ1 2025: $821.0MQ1 ’25$821.0MQ2 2025: $1.8BQ2 ’25$1.8BQ3 2025: $775.0MQ3 ’25$775.0MQ4 2025: -$209.0MQ4 ’25-$209.0MQ1 2026: $4.1BQ1 ’26$4.1BQ2 2026: $1.6BQ2 ’26$1.6BQ3 2026: $1.0BQ3 ’26$1.0B
Data
Q4 2024$384.0M
Q1 2025$821.0M
Q2 2025$1.8B
Q3 2025$775.0M
Q4 2025-$209.0M
Q1 2026$4.1B
Q2 2026$1.6B
Q3 2026$1.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$45.4Bd$48.9B$49.8B$50.7B$49.7Bd$50.2B$50.5B$51.4B
Operating income$673.0Md$3.2B$2.4B$1.3B$309.0Md$2.1B$1.8B$1.3B
Operating margin1.5%6.5%4.9%2.6%0.6%4.2%3.5%2.5%
Net income$418.0Md$2.2B$1.7B$1.2B$547.0Md$1.8B$1.5B$1.4B
Diluted EPS—$9.61$7.72$5.32—$8.00$6.71$6.27
Operating cash flow$706.0Md$1.0B$2.1Bd$1.1Bd$84.0Md$4.3B$1.9Bd$1.3Bd
Capital expenditure$322.0Md$196.0M$267.0Md$360.0Md$293.0Md$235.0M$287.0Md$267.0Md
Free cash flow$384.0M$821.0M$1.8B$775.0M-$209.0M$4.1B$1.6B$1.0B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings